DOCSLIB.ORG

"2N Ó - H a A.N () -Si-'-RH "',O '-S'a AO Or Patent Application Publication Jul

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
US 2006O154325A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0154325 A1 Bogyo et al. (43) Pub. Date: Jul. 13, 2006 (54) SYNTHESIS OF EPOXIDE BASED Publication Classification INHIBITORS OF CYSTEINE PROTEASES (51) Int. Cl. CI2O I/37 (2006.01) (76) Inventors: Matthew Bogyo, Redwood City, CA C07K 7/08 (2006.01) (US); Steven H.L. Verhelst, Stanford, C07D 303/08 (2006.01) CA (US) (52) U.S. Cl. ............................. 435/23: 530/402; 549/551 Correspondence Address: (57) ABSTRACT PETERS VERNY JONES & SCHMITT, L.L.P. 425 SHERMANAVENUE SUTE 230 Epoxide based cysteine protease inhibitors containing pep PALO ALTO, CA 94.306 (US) tide derivatives and methods for synthesizing them in sold phase are disclosed. Preferably, an epoxy succinyl “war head' (for binding to the enzyme) is prepared, having two (21) Appl. No.: 11/329,818 amino acid residues or residue-like structures on either side. Natural and non-natural amino acids may be used. The present process may be carried out entirely on a solid (22) Filed: Jan. 10, 2006 Support, with the proviso that a dipeptide like group is prepared prior to coupling to one side of the Supported Related U.S. Application Data complex. The method lends itself to more efficient inhibitor synthesis, and may be employed with mixtures of peptide (60) Provisional application No. 60/642,891, filed on Jan. compounds, and various modifications of epoxides to create 10, 2005. diverse libraries of inhibitors. Fmoc-NH-AA-OH 1) 20%diorari Piperdine all- AA A 1 0 2 O N-Fmoc di H 1 AA if m RNK Tentage Resin Step 1 2)) Fmoc-NH-AA-OH2 2 1) 20% Piperdine Step 2 Step 3 2) epoxide-NP ester NaOH (): N AA 1 N o al- S H AA O H O O S1NÓ H A A. () OH Step 4 is us N ---N-(i- O Et O A Ao NHR HO-R Step 6 AA o H A A 1 H o 1N N 1R N - NN O 1 NR Ó H A A. () H Ö A.A. () Step 7 Step 8 TFAIHOITIS TFAIHOITIS AA H o AA 1 o "2N Ó - H A A.N () -si-'-RH "',O '-s'A AO or Patent Application Publication Jul. 13, 2006 Sheet 1 of 5 US 2006/0154325 A1 Fig. 1 Fmoc-NH-AA-OH 1) 20%of Piperdineorarr; d) H d H AA RNK Tentage Resin 2) Fmoc-NH-AA-OH 2 1) 20% Piperdine Step 2 Step 3 2) epoxide-NP ester A A O O NaOH 1sloe AAO AA 10 H o N S. SNN 1s-orr1a. A AO Step 7 TFAIHOITIS TFAIHOITIS AAC H o AA H o HN - N ana HN S N-N-si-'o ~ a'sO A AO stra O 1. A A2 O O 1 R Patent Application Publication Jul. 13, 2006 Sheet 2 of 5 US 2006/0154325 A1 Fig. 2 20% Piperadine Patent Application Publication Jul. 13, 2006 Sheet 4 of 5 US 2006/0154325 A1 Fig. 4 Probe JPM ACSV4ACSV5 ACSW4ACSW6 TRSV4 TRSV5 OE Conc (M) 04 2 10 04 2 to Patent Application Publication Jul. 13, 2006 Sheet 5 of 5 US 2006/0154325 A1 Fig. 5 lane Cat Z Cat B catcCath US 2006/0154325 A1 Jul. 13, 2006 SYNTHESIS OF EPOXDE BASED INHIBITORS OF 0.011) Joyce et al. (Cancer Cell, 2004, 5, 443-453) have CYSTEINE PROTEASES shown the importance of the cysteine cathepsin proteases in a number of processes related to cancer progression. These CROSS-REFERENCE TO RELATED processes include tumor growth, angiogenesis, and metasta APPLICATIONS sis. This article discloses that a general, covalent inhibitor, 0001. This application claims priority to provisional which specifically targets the cathepsin protease family can patent application Ser. No. 60/642,891, filed Jan. 10.2005, be administered systemically to transgenic mice that develop entitled “Synthesis of Epoxide Based Inhibitors of Cysteine a multi-stage form of pancreatic cancer and lead to reduced Protease,” and hereby incorporated by reference. tumor burden, metastasis and angiogenesis. STATEMENT OF GOVERNMENTAL SUPPORT 0012 Specifically, Joyce et al. disclose the inhibition of six cathepsin proteases by compounds DCG-04, 530/550 0002 This invention was made during work supported by Biodipy DCG-04, and JPM-OEt. These general covalent U.S. National Institutes of Health under grant U54 epoxide based inhibitors showed little or no general toxicity RR020843. The government has certain rights in this inven when administered to normal mice over a period of several tion. weeks. This work (including work by the present inventors) Suggests that cathepsin cysteine proteases represent a valid REFERENCE TO SEQUENCE LISTING OR COMPACT DISK target for anti-cancer therapeutics. 0003) None. 0013 The general epoxide scaffold for JPM-OEt is based on the natural product E-64, which was discovered to be a BACKGROUND OF THE INVENTION natural product inhibitor of cysteine protease in 1978 (Hanada, K. et al. Agric. Biol. Chem. 1978 42, 523-528 and 0004) 1. Field of the Invention 529-536). 0005 The present invention relates to the synthesis of organic molecules useful in the labeling or inhibition of cysteine proteases. HO O H O 0006 2. Related Art H N 0007 Cysteine proteases are proteolytic enzymes, which N w OEt utilize a cysteine residue for their catalytic activity. They can H be grouped in at least 30 protein families. Each family O H contains proteins with similar amino acid sequences and evolutionarily conserved sequence motifs, which are reflected in the family members similar 3D structures. JPM-OEt 0008 Proteases in Family C1 (the papain family) include O H O mammalian enzymes such as cathepsins B and L, which are H H O thought to be involved in cancer growth and metastasis. HN NS-1a1n N N w '' OH Cathepsin K is considered to be involved in bone degrada H 2. tion an osteoporosis. Family C1 also includes parasitic NH O H enzymes being essential for the parasite-host interaction (e.g. cruzipain from Trypanosoma cruzi—ausing Chagas disease, and falcipain from Plasmodium falciparum-caus E-64 ing malaria). 0009 Enzymes belonging to Family C13 (the legumain family) have been shown to play key roles in antigen 0014) The related compound JPM-565 is identical to presentation. Interleukin converting enzyme (ICE) and other JPM-OEt except that the ethyl ester is converted to the free enzymes belonging to Family C14 (the caspase family) have carboxylic acid. gained much interest recently, as key mediators of apoptosis. Many proteases of pathogenic bacteria are virulence factors 0015 These classes of compounds (i.e. having a succinyl and cause severe problems for the host at infections, such as epoxy component) have been used as cysteine protease gingipains (Family C25) of Porhyromonas gingivalis in inhibitors since 1978. A number of research groups have periodontitis and streptopain (Family C10) from Streptococ synthesized analogs of the general epoxide structure over the CuS pyogenes. past 20+ years and the crystal structure of E-64 bound to 0010 Proteolysis controls a number of essential biologi various cysteine proteases in the cathepsin family were cal processes ranging from cell division to cell death. reported as early as 1989. Amongst the cysteine proteases, the lysosomal cathepsins play important roles in a number of human diseases. Ref. 6 0016. Meara and Rich, J. Med. Chem. 1996, 39, 3357 However, this family displays similar substrate preferences 3366 outline some basic SAR data on the epoxysuccinyl making the development of tools to study individual cathe inhibitors of cysteine cathepsins. They worked with the psins a challenging task. basic epoxy Succinyl structure US 2006/0154325 A1 Jul. 13, 2006 bine tags for visualization or purification with warheads that covalently attach to the active sites of enzymatic targets in OR an activity-dependant manner. Using this approach, a spe O w cific protein or protein family can be readily monitored in S- O complex protein mixtures, intact cells, and even in vivo. O Ref. 3 Furthermore, enzyme class specific probes can be R used to develop screens for small molecule inhibitors that can be used functional studies. Ref. 4.5 Therefore, methods that will facilitate the development of novel ABPs have great 0017. They prepared molecules where OR was replaced value for advancing the use of this technology. The natural by a substituted carboxamides, e.g. where the OR was product E-64 Ref. 1 inhibits cysteine proteases via cova replaced with NH-CH(CH)—C(O) NH-CH. lent attachment to the active site sulfhydryl nucleophile. 0018. The use of JPM-565, which is the free acid version This reagent contains a leucine residue that mimics the of JPM-OEt, is disclosed in Shi, et al. J. Biol. Chem. 1992, critical P2 residue of a substrate and therefore binds effi 267, 7258-7262. This paper discloses the molecular cloning ciently in the S2 specificity pocket of virtually all cysteine and expression of human alveolar macrophage cathepsin S. cathepsins. As a result this reagent is a broad-spectrum and its active site labeling with JPM-565. Other inhibitors, inhibitor and activity probe. such as E-64, cystatin c. Cbz-TYr-Tyrco-butyl)-CHN are also disclosed. 0023. One of the first ABPs reported using the epoxide warhead, DCG-04 Ref. 2), has found widespread use for a 0019 Greenbaum et al. Chem. Biol. 2002, 9, 1085-1094 number of functional studies of the cysteine cathepsins. also describe cysteine protease inhibitors. It is noted there However, this general probe makes use of a single peptide that the epoxide class of cysteine protease binding com piece that makes contacts with only one side of the protease pounds has a chiral structure, e.g.
Load more

Recommended publications
  • Cysteine Proteinases of Microorganisms and Viruses
    ISSN 00062979, Biochemistry (Moscow), 2008, Vol. 73, No. 1, pp. 113. © Pleiades Publishing, Ltd., 2008. Original Russian Text © G. N. Rudenskaya, D. V. Pupov, 2008, published in Biokhimiya, 2008, Vol. 73, No. 1, pp. 317. REVIEW Cysteine Proteinases of Microorganisms and Viruses G. N. Rudenskaya1* and D. V. Pupov2 1Faculty of Chemistry and 2Faculty of Biology, Lomonosov Moscow State University, 119991 Moscow, Russia; fax: (495) 9393181; Email: [email protected] Received May 7, 2007 Revision received July 18, 2007 Abstract—This review considers properties of secreted cysteine proteinases of protozoa, bacteria, and viruses and presents information on the contemporary taxonomy of cysteine proteinases. Literature data on the structure and physicochemical and enzymatic properties of these enzymes are reviewed. High interest in cysteine proteinases is explained by the discovery of these enzymes mostly in pathogenic organisms. The role of the proteinases in pathogenesis of several severe diseases of human and animals is discussed. DOI: 10.1134/S000629790801001X Key words: cysteine proteinases, properties, protozoa, bacteria, viruses Classification and Catalytic Mechanism papain and related peptidases showed that the catalytic of Cysteine Proteinases residues are arranged in the following order in the polypeptide chain: Cys, His, and Asn. Also, a glutamine Cysteine proteinases are peptidyl hydrolases in residue preceding the catalytic cysteine is also important which the role of the nucleophilic group of the active site for catalysis. This residue is probably involved in the for is performed by the sulfhydryl group of a cysteine residue. mation of the oxyanion cavity of the enzyme. The cat Cysteine proteinases were first discovered and investigat alytic cysteine residue is usually followed by a residue of ed in tropic plants.
    [Show full text]
  • Characterization of Cathepsin L Genes and Their Cdnas in the Brine Shrimp, Artemia Franciscana
    University of Windsor Scholarship at UWindsor Electronic Theses and Dissertations Theses, Dissertations, and Major Papers 2006 Characterization of cathepsin L genes and their cDNAs in the brine shrimp, Artemia franciscana. Jian Ping Cao University of Windsor Follow this and additional works at: https://scholar.uwindsor.ca/etd Recommended Citation Cao, Jian Ping, "Characterization of cathepsin L genes and their cDNAs in the brine shrimp, Artemia franciscana." (2006). Electronic Theses and Dissertations. 1398. https://scholar.uwindsor.ca/etd/1398 This online database contains the full-text of PhD dissertations and Masters’ theses of University of Windsor students from 1954 forward. These documents are made available for personal study and research purposes only, in accordance with the Canadian Copyright Act and the Creative Commons license—CC BY-NC-ND (Attribution, Non-Commercial, No Derivative Works). Under this license, works must always be attributed to the copyright holder (original author), cannot be used for any commercial purposes, and may not be altered. Any other use would require the permission of the copyright holder. Students may inquire about withdrawing their dissertation and/or thesis from this database. For additional inquiries, please contact the repository administrator via email ([email protected]) or by telephone at 519-253-3000ext. 3208. CHARACTERIZATION OF CATHEPSIN L GENES AND THEIR cDNAs IN THE BRINE SHRIMP, ARTEMIA FRANCISCANA By: JianPing Cao A Thesis Submitted to the Faculty of Graduate Studies and Research through the Department of Biological Sciences in Partial Fulfillment of the Requirements for the Degree of Master of Science at the University of Windsor Windsor, Ontario, Canada 2006 Reproduced with permission of the copyright owner.
    [Show full text]
  • Proteolytic Enzymes in Grass Pollen and Their Relationship to Allergenic Proteins
    Proteolytic Enzymes in Grass Pollen and their Relationship to Allergenic Proteins By Rohit G. Saldanha A thesis submitted in fulfilment of the requirements for the degree of Masters by Research Faculty of Medicine The University of New South Wales March 2005 TABLE OF CONTENTS TABLE OF CONTENTS 1 LIST OF FIGURES 6 LIST OF TABLES 8 LIST OF TABLES 8 ABBREVIATIONS 8 ACKNOWLEDGEMENTS 11 PUBLISHED WORK FROM THIS THESIS 12 ABSTRACT 13 1. ASTHMA AND SENSITISATION IN ALLERGIC DISEASES 14 1.1 Defining Asthma and its Clinical Presentation 14 1.2 Inflammatory Responses in Asthma 15 1.2.1 The Early Phase Response 15 1.2.2 The Late Phase Reaction 16 1.3 Effects of Airway Inflammation 16 1.3.1 Respiratory Epithelium 16 1.3.2 Airway Remodelling 17 1.4 Classification of Asthma 18 1.4.1 Extrinsic Asthma 19 1.4.2 Intrinsic Asthma 19 1.5 Prevalence of Asthma 20 1.6 Immunological Sensitisation 22 1.7 Antigen Presentation and development of T cell Responses. 22 1.8 Factors Influencing T cell Activation Responses 25 1.8.1 Co-Stimulatory Interactions 25 1.8.2 Cognate Cellular Interactions 26 1.8.3 Soluble Pro-inflammatory Factors 26 1.9 Intracellular Signalling Mechanisms Regulating T cell Differentiation 30 2 POLLEN ALLERGENS AND THEIR RELATIONSHIP TO PROTEOLYTIC ENZYMES 33 1 2.1 The Role of Pollen Allergens in Asthma 33 2.2 Environmental Factors influencing Pollen Exposure 33 2.3 Classification of Pollen Sources 35 2.3.1 Taxonomy of Pollen Sources 35 2.3.2 Cross-Reactivity between different Pollen Allergens 40 2.4 Classification of Pollen Allergens 41 2.4.1
    [Show full text]
  • Developing Methods to Understand and Engineer Protease Cleavage Specificity
    Developing methods to understand and engineer protease cleavage specificity A Dissertation SUBMITTED TO THE FACULTY OF THE UNIVERSITY OF MINNESOTA BY Michael Douglas Lane IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY Burckhard Seelig September 2016 © Michael D Lane, 2016 Acknowledgements I would like to thank the many people who supported me along the way towards completing my thesis. Above all, I thank my advisor, Dr. Burckhard Seelig, who gave me the opportunity to pursue my ideas, embraced my research with thoughtful criticism and relentless optimism, and shaped my scientific approach through challenging me to be the best I can be. I also would like to thank previous members of the Seelig lab, Dr. Misha Golynskiy, Dr. John Haugner, Dr. Dana Morrone, and Dr. Aleardo Morelli, for being good friends and the many scientific discussions we had that guided me through the rough experiments. To the new Seelig lab members, especially Dr. Matilda Newton, Dr. Yari Cabezas, and Dr. Nisha Kanwar, thank you for your critical feedback, friendship, and taking away all my lab responsibilities. To the MSTP, I would like to thank Dr. Yoji Shimizu, Susan Shurson, and Nicholas Berg for their unending help guiding through the woven MD/PhD program. In particular, I thank the MSTP leadership for allowing me to pursue the program tailored to my interests. To my thesis committee, thank you for your support through the years. From annual reviews, to informal discussions, to grant application drafts, your feedback molded my abilities and experience. To my friends and family, especially my wife, Dr.
    [Show full text]
  • Regulation and Functions of Acute Phase Proteins
    ACUTE PHASE ROTEI REG ULATION AND FUNCTIONS OF ACUTE PHASE PROTEINS Edited by Fra cisco Veas INTECH ACUTE PHASE PROTEINS – REGULATION AND FUNCTIONS OF ACUTE PHASE PROTEINS Edited by Francisco Veas Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins Edited by Francisco Veas Published by InTech Janeza Trdine 9, 51000 Rijeka, Croatia Copyright © 2011 InTech All chapters are Open Access articles distributed under the Creative Commons Non Commercial Share Alike Attribution 3.0 license, which permits to copy, distribute, transmit, and adapt the work in any medium, so long as the original work is properly cited. After this work has been published by InTech, authors have the right to republish it, in whole or part, in any publication of which they are the author, and to make other personal use of the work. Any republication, referencing or personal use of the work must explicitly identify the original source. Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published articles. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book. Publishing Process Manager Davor Vidic Technical Editor Teodora Smiljanic Cover Designer Jan Hyrat Image Copyright Ali Mazraie Shadi, 2011. Used under license from Shutterstock.com First published September, 2011 Printed in Croatia A free online edition of this book is available at www.intechopen.com Additional hard copies can be obtained from [email protected] Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins, Edited by Francisco Veas p.
    [Show full text]
  • Epidemiology and Pathogenesis of Moraxella Catarrhalis Colonization
    Chirality: The Key to Specific Bacterial Protease-Based Diagnosis? Wendy E. Kaman ISBN 978-94-6169-451-5 © W.E. Kaman, Rotterdam, 2014 All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by means without prior permission of the author, or where appropriate, the publisher of the articles. The printing of this thesis was financially supported by the Nederlandse Vereniging voor Medische Microbiologie. Layout and printing: Optima Grafische Communicatie Cover design: Suede Design (www.suededesign.nl) Chirality: The Key to Specific Bacterial Protease-Based Diagnosis? Chiraliteit: de sleutel tot bacterie-specifieke protease-gebaseerde diagnostiek? Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de Rector Magnificus Prof. dr. H.A.P. Pols en volgens besluit van het College voor Promoties De openbare verdediging zal plaats vinden op 24 januari om 9:30 uur door Wendy Esmeralda Kaman geboren te `s-Gravenhage Promotiecommissie Promotor: Prof. dr. H.P. Endtz Overige leden: Prof. dr. E.C.I. Veerman Prof. dr. W. Crielaard Prof. dr. dr. A. van Belkum Co-promotoren: Dr. F.J. Bikker Dr. J.P. Hays It`s all about cleavage! Contents Amino acids 11 Introduction Chapter 1. General introduction, aim and outline of the thesis. 15 Diagnosis Chapter 2. Evaluation of a D-amino-acid-containing fluorescence resonance 39 energy transfer (FRET-) peptide library for profiling prokaryotic proteases. Chapter 3. Highly specific protease-based approach for detection ofPorphy- 59 romonas gingivalis in diagnosis of periodontitis. Chapter 4. Comparing culture, real-time PCR and FRET-technology for de- 81 tection of Porphyromonas gingivalis in patients with or without peri-implant infections.
    [Show full text]
  • Families and Clans of Cysteine Peptidases
    Families and clans of eysteine peptidases Alan J. Barrett* and Neil D. Rawlings Peptidase Laboratory. Department of Immunology, The Babraham Institute, Cambridge CB2 4AT,, UK. Summary The known cysteine peptidases have been classified into 35 sequence families. We argue that these have arisen from at least five separate evolutionary origins, each of which is represented by a set of one or more modern-day families, termed a clan. Clan CA is the largest, containing the papain family, C1, and others with the Cys/His catalytic dyad. Clan CB (His/Cys dyad) contains enzymes from RNA viruses that are distantly related to chymotrypsin. The peptidases of clan CC are also from RNA viruses, but have papain-like Cys/His catalytic sites. Clans CD and CE contain only one family each, those of interleukin-ll3-converting enz3wne and adenovirus L3 proteinase, respectively. A few families cannot yet be assigned to clans. In view of the number of separate origins of enzymes of this type, one should be cautious in generalising about the catalytic mechanisms and other properties of cysteine peptidases as a whole. In contrast, it may be safer to gener- alise for enzymes within a single family or clan. Introduction Peptidases in which the thiol group of a cysteine residue serves as the nucleophile in catalysis are defined as cysteine peptidases. In all the cysteine peptidases discovered so far, the activity depends upon a catalytic dyad, the second member of which is a histidine residue acting as a general base. The majority of cysteine peptidases are endopeptidases, but some act additionally or exclusively as exopeptidases.
    [Show full text]
  • Emerging Evidence in IBD
    International Journal of Molecular Sciences Review Gut Serpinome: Emerging Evidence in IBD Héla Mkaouar 1, Vincent Mariaule 1, Soufien Rhimi 1, Juan Hernandez 2 , Aicha Kriaa 1, Amin Jablaoui 1, Nizar Akermi 1, Emmanuelle Maguin 1 , Adam Lesner 3 , Brice Korkmaz 4 and Moez Rhimi 1,* 1 Microbiota Interaction with Human and Animal Team (MIHA), Micalis Institute, AgroParisTech, Université Paris-Saclay, INRAE, 78350 Jouy-en-Josas, France; [email protected] (H.M.); [email protected] (V.M.); soufi[email protected] (S.R.); [email protected] (A.K.); [email protected] (A.J.); [email protected] (N.A.); [email protected] (E.M.) 2 Department of Clinical Sciences, Nantes-Atlantic College of Veterinary Medicine and Food Sciences (Oniris), University of Nantes, 101 Route de Gachet, 44300 Nantes, France; [email protected] 3 Faculty of Chemistry, University of Gdansk, Uniwersytet Gdanski, Chemistry, Wita Stwosza 63, PL80-308 Gdansk, Poland; [email protected] 4 INSERM UMR-1100, “Research Center for Respiratory Diseases” and University of Tours, 37032 Tours, France; [email protected] * Correspondence: [email protected] Abstract: Inflammatory bowel diseases (IBD) are incurable disorders whose prevalence and global socioeconomic impact are increasing. While the role of host genetics and immunity is well docu- mented, that of gut microbiota dysbiosis is increasingly being studied. However, the molecular basis of the dialogue between the gut microbiota and the host remains poorly understood. Increased activity of serine proteases is demonstrated in IBD patients and may contribute to the onset and the maintenance of the disease.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Ides and Speb
    Studies on secreted cysteine proteases of Streptococcus pyogenes - IdeS and SpeB Reine Vindebro Department of Molecular Biology Umeå University Umeå 2014 Responsible publisher under swedish law: the Dean of the Medical Faculty This work is protected by the Swedish Copyright Legislation (Act 1960:729) ISBN: 978-91-7601-048-8 ISSN: 0346-6612 New series nr: 1646 Electronic version available at http://umu.diva-portal.org/ Printed by: KBC printing service (Umeå University) Umeå, Sweden 2014 To Sofia and Rasmus. i ii Table of Contents Abstract iv List of Publications and Manuscripts v Abbreviations vi 1 Introduction 1 1.1 Streptococcus pyogenes 1 1.1.1 Virulence factors 2 1.2 Proteases in general 3 1.3 Immunoglobulin G (IgG) 3 1.4 IdeS 5 1.4.1 Discovery 5 1.4.2 Protein properties and structure 6 1.4.3 Substrate specificity and binding site on IgG 7 1.4.4 Enzymatic constants 9 1.4.5 Effect of IgG cleavage 10 1.4.6 IdeS as a dimer 11 1.4.7 Allelic Variation 12 1.4.8 Other functions of IdeS 13 1.4.9 Prevalence of IdeS in S. pyogenes strains 14 1.4.10 Regulatory control 14 1.4.11 Importance as a virulence factor 15 1.4.12 Homologues in other bacterial species 16 1.4.13 Therapeutic potential 17 1.4.14 Use as a laboratory tool 17 1.5 SpeB 18 1.5.1 Discovery 18 1.5.2 Regulatory control 18 1.5.3 Structure of SpeB and the potential dimer 18 1.5.4 Functions of, and substrates for, SpeB 19 1.5.5 IgG as a substrate for SpeB 20 1.5.6 SpeB is, or is not, an important virulence factor 21 1.6 IdeS and SpeB as virulence factors 22 2 Methods 24 2.1 General methods 24 2.2 Detecting degradation of IgG by IdeS 25 3 Results and discussion 28 3.1 Paper I 28 3.2 Paper II 30 3.3 Paper III 31 3.4 Paper IV 33 3.5 Paper V 34 Conclusions 36 Acknowledgements 37 References 38 iii Abstract The pathogen Streptococcus pyogenes is a significant cause of human morbidity and mortality.
    [Show full text]
  • Molecular Mechanisms of Streptococcus Pyogenes Tissue Colonization and Invasion Antonin Weckel
    Molecular mechanisms of Streptococcus pyogenes tissue colonization and invasion Antonin Weckel To cite this version: Antonin Weckel. Molecular mechanisms of Streptococcus pyogenes tissue colonization and invasion. Microbiology and Parasitology. Université Sorbonne Paris Cité, 2018. English. NNT : 2018US- PCB097. tel-02984777 HAL Id: tel-02984777 https://tel.archives-ouvertes.fr/tel-02984777 Submitted on 1 Nov 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Université Paris Descartes Ecole doctorale BioSPC Institut Cochin INSERM U1016 / Equipe Barrières et Pathogènes Molecular mechanisms of Streptococcus pyogenes tissue colonization and invasion By Antonin WECKEL PhD Thesis in Microbiology Directed by Agnès Fouet Thesis defense: 30th of October 2018 Jury members: Pr Anna NORRBY-TEGLUND Reviewer Dr Pascale SERROR Reviewer Pr François VANDENESCH Examiner Dr Philippe BOUSSO Examiner Dr Agnès FOUET PhD supervisor “We have to remember that what we observe is not nature herself, but nature exposed to our method of questioning” Werner Heisenberg Physics and Philosophy: The Revolution in Modern Science (1958) Acknowledgements I would like to thank Pascale Serror, Anna Norrby-Teglund, François Vandenesch and Philippe Bousso for having kindly accepted to be part of my defense jury, in particular to Anna Norrby- Teglund who came from Sweden for my defense.
    [Show full text]